| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/17/2004 | WO2004050702A2 Novel ifngamma-like polypeptides |
| 06/17/2004 | WO2004050701A1 Bone growth factor |
| 06/17/2004 | WO2004050700A1 Process for preparating concentrated thrombin solutions and use in fibrin glue |
| 06/17/2004 | WO2004050692A2 Fusion of the e2 protein of csfv with kdel , vts and/or ubiquitin for expression in transgenic plants for vaccine production |
| 06/17/2004 | WO2004050690A1 NOVEL χ-CONOTOXIN PEPTIDES (-I) |
| 06/17/2004 | WO2004050689A2 Aza-peptides |
| 06/17/2004 | WO2004050688A1 NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| 06/17/2004 | WO2004050687A2 Cyclosporins for the treatment of autoimmune diseases |
| 06/17/2004 | WO2004050685A2 Antifungal therapeutic agents |
| 06/17/2004 | WO2004050679A2 Mutant glycoproteins |
| 06/17/2004 | WO2004050674A2 Methods and materials for modulating trpm2 |
| 06/17/2004 | WO2004050125A1 Inhibitor of proliferation and/or infiltration of tumor cells |
| 06/17/2004 | WO2004050124A2 Chimaeric molecules |
| 06/17/2004 | WO2004050118A1 Cysteine protease inhibitor |
| 06/17/2004 | WO2004050117A1 Proteins involved in the regulation of energy homeostasis |
| 06/17/2004 | WO2004050116A1 Protease inhibitor |
| 06/17/2004 | WO2004050115A2 Combination treatment using exendin-4 and thiazolidinediones |
| 06/17/2004 | WO2004050114A1 Novel agent for improving neurotransmission failure |
| 06/17/2004 | WO2004050113A1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE |
| 06/17/2004 | WO2004050112A1 Intratumor administration of heat shock protein and its combination tumor therapy with cell toxin |
| 06/17/2004 | WO2004050101A2 Formulations useful against hepatitis c virus infections |
| 06/17/2004 | WO2004050096A2 Phosphoantigens for regulating an immune response |
| 06/17/2004 | WO2004050090A1 Rapamycin and il-10 for the treatment of immune diseases |
| 06/17/2004 | WO2004050076A1 Use of a histone deacetylase inhibitor for treating muscular dystrophies |
| 06/17/2004 | WO2004050041A2 Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
| 06/17/2004 | WO2004050037A2 Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease |
| 06/17/2004 | WO2004050027A2 Materials and methods for treating ocular-related disorders |
| 06/17/2004 | WO2004050023A2 Treatment of diseases and conditions mediated by increased phosphorylation |
| 06/17/2004 | WO2004050013A2 Material compositions and related systems and methods for treating cardiac conditions |
| 06/17/2004 | WO2004050007A2 Mammalian bt-42 proteins involved in the regulation of energy homeostasis |
| 06/17/2004 | WO2004049964A2 Drug to be introduced tooth or periodontal tissue and apparatus for introducing drug to tooth or periodontal tissue |
| 06/17/2004 | WO2004049901A2 Methods of treating cerebral ischemia |
| 06/17/2004 | WO2004049830A1 Sustained improver of muscular fatigue |
| 06/17/2004 | WO2004044589A3 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3) |
| 06/17/2004 | WO2004033677A3 Secreted acid phosphatase (sapm) is present only in pathogenic mycobacteria and expressed selectively at acidic ph |
| 06/17/2004 | WO2004031233A9 Novel chemokine-like polypeptides |
| 06/17/2004 | WO2004029089A3 Novel angiogenesis target and uses thereof |
| 06/17/2004 | WO2004018002A3 Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells |
| 06/17/2004 | WO2004015075A3 SHORT INTERFERING RNAs HAVING A HAIRPIN STRUCTURE CONTAINING A NON-NUCLEOTIDE LOOP |
| 06/17/2004 | WO2004014351A3 Use of cgrp antagonist compounds for treatment of psoriasis |
| 06/17/2004 | WO2004013282A3 Bis (amino acid) molecular scaffolds |
| 06/17/2004 | WO2004012762A3 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 06/17/2004 | WO2004011098A3 Golf shaft with adjustable stiffness and frequency |
| 06/17/2004 | WO2004003164A3 Methods of organ regeneration |
| 06/17/2004 | WO2004003133A3 Pain signaling molecules |
| 06/17/2004 | WO2004002404A3 Compositions and method for enhanced mucosal delivery of interferon beta |
| 06/17/2004 | WO2003105763A3 Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
| 06/17/2004 | WO2003102138A3 Elongase genes and uses thereof |
| 06/17/2004 | WO2003073351A3 Screening process |
| 06/17/2004 | WO2003064992A3 Novel immunoadhesins for treating and preventing toxicity and pathogen-mediated diseases |
| 06/17/2004 | WO2003059387A3 Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis |
| 06/17/2004 | WO2003053997A3 Methods of increasing endogenous erythropoietin (epo) |
| 06/17/2004 | WO2003053334A3 Compositions and methods for the diagnosis and treatment of tumor |
| 06/17/2004 | WO2003051911A3 Gmg-5 polynucleotides and polypeptides and uses thereof |
| 06/17/2004 | WO2003051380A3 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
| 06/17/2004 | WO2003032810A3 Treatment and diagnosis of insulin resistant states |
| 06/17/2004 | WO2003026566A3 Atlastin |
| 06/17/2004 | WO2003023007A8 Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39 |
| 06/17/2004 | WO2003018632A3 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| 06/17/2004 | WO2002102309A3 Formulation of lymphokines and method of use thereof for local or bath local and systemic control of proliferative cell disorders |
| 06/17/2004 | US20040116699 Melanocortin receptor agonists |
| 06/17/2004 | US20040116678 Cardiac hypertrophy factor and uses therefor |
| 06/17/2004 | US20040116671 Novel polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040116670 Comprises polypeptides associated with cytoplasmic network of protein fibers that mediate cell shape, structure, and movement for diagnosis, treatment and prevention of cell proliferative, viral, neurological disorders |
| 06/17/2004 | US20040116669 Prostaglandin ep1 receptor |
| 06/17/2004 | US20040116668 Zis-sr nucleic acid and amino acid sequences involved in the regulated secretory pathway and/or the regulation of the neuroendocrine phenotype (nep) |
| 06/17/2004 | US20040116667 Tyrosinase-related gene (TRP2) protein comprising human leukocyte antigen cytotoxic binding recognition points for identifying modulators for diagnosis, prevention and treatment of cancer ; immunotherapy |
| 06/17/2004 | US20040116661 Virulence peptides from attenuated microorganism for identifying microbiocides and developing vaccines which prevent infection; veterinary medicine |
| 06/17/2004 | US20040116659 Helicase inhibitors |
| 06/17/2004 | US20040116657 Modified peptide |
| 06/17/2004 | US20040116656 Memory-enhancing peptides and the use thereof |
| 06/17/2004 | US20040116655 Viricides |
| 06/17/2004 | US20040116653 Compositions containing anti-HIV peptides and methods for use |
| 06/17/2004 | US20040116652 Method for producing and using novel human defensins as biologically active proteins for treating infections and other diseases |
| 06/17/2004 | US20040116649 Polyoxyethylene glycol; purity, storage stability |
| 06/17/2004 | US20040116636 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 06/17/2004 | US20040116496 Asymmetric Disulfides and methods of using same |
| 06/17/2004 | US20040116372 to decrease the number of cells which may accumulate in chronic inflammatory disease by enhancing apoptosis at the site of increased cell number via gene therapy |
| 06/17/2004 | US20040116369 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
| 06/17/2004 | US20040116366 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
| 06/17/2004 | US20040116365 Modulation of Lck expression |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116352 Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 |
| 06/17/2004 | US20040116351 Administering to a patient an opiate destruction-inhibitor |
| 06/17/2004 | US20040116350 Contacting the cell with an antioxidant, wherein the antioxidant is effective in reducing antibody mediated generation of superoxide or hydrogen peroxide in the cell |
| 06/17/2004 | US20040116349 Selecting patient displaying symptoms of heart disease; administering dose of growth factor protein formulation by oral inhalation; monitoring levels of CPK-MB; administering one or more additional doses of a second growth factor protein |
| 06/17/2004 | US20040116346 For use in therapy of anemia, as well as in other functions associated with assays for EPO-R, studying EPO and EPO-R function, purification of EPO-R |
| 06/17/2004 | US20040116345 Novel albumin-free factor VIII formulations |
| 06/17/2004 | US20040116344 Immunomodulatory properties of bip |
| 06/17/2004 | US20040116343 For inducing liver regeneration in a damaged liver tissue region of an individual |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040116341 Administering active ingredient which is RANTES protein or an expression system therefor effective to prevent or ameliorate paramyxovirus infection |
| 06/17/2004 | US20040116340 Funtional fragment of the lectine receptor |
| 06/17/2004 | US20040116339 Compounds that bind P2Y2 or P2Y1 receptors |
| 06/17/2004 | US20040116338 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 06/17/2004 | US20040116337 Soluble cyclic analogues of beta amyloid peptide |
| 06/17/2004 | US20040116336 Peptide derivatives |
| 06/17/2004 | US20040116335 Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I |
| 06/17/2004 | US20040116334 Useful as anti-bacterial agents |
| 06/17/2004 | US20040116331 Novel role for GLP-1 to mediate responses to disparate stressors |